{"organizations": [], "uuid": "1fd362757fce73714eea041232731be07be447eb", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-seattle-genetics-says-fda-grants-i/brief-seattle-genetics-says-fda-grants-its-hodgkin-lymphoma-treatment-priority-review-status-idUSASB0BZEU", "country": "US", "domain_rank": 408, "title": "BRIEF-Seattle Genetics says FDA grants its Hodgkin Lymphoma treatment priority review status", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-02T15:10:00.000+02:00", "replies_count": 0, "uuid": "1fd362757fce73714eea041232731be07be447eb"}, "author": "", "url": "https://www.reuters.com/article/brief-seattle-genetics-says-fda-grants-i/brief-seattle-genetics-says-fda-grants-its-hodgkin-lymphoma-treatment-priority-review-status-idUSASB0BZEU", "ord_in_thread": 0, "title": "BRIEF-Seattle Genetics says FDA grants its Hodgkin Lymphoma treatment priority review status", "locations": [], "entities": {"persons": [{"name": "hodgkin lymphom", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "hodgkin lymphoma", "sentiment": "negative"}, {"name": "fda", "sentiment": "negative"}, {"name": "brief-seattle genetics", "sentiment": "negative"}, {"name": "seattle genetics inc", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "pdufa", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "seattle genetics inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 2, 2018 / 1:11 PM / in 10 minutes BRIEF-Seattle Genetics says FDA grants its Hodgkin Lymphoma treatment priority review status Reuters Staff 1 Min Read \nJan 2 (Reuters) - Seattle Genetics Inc: \n* FDA ACCEPTS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION AND GRANTS PRIORITY REVIEW FOR ADCETRISÂ® (BRENTUXIMAB VEDOTIN) IN FRONTLINE ADVANCED HODGKIN LYMPHOMA \n* SEATTLE GENETICS INC - FDA GRANTED PRIORITY REVIEW FOR APPLICATION, AND PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE IS MAY 1, 2018 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-02T15:10:00.000+02:00", "crawled": "2018-01-02T15:23:52.065+02:00", "highlightTitle": ""}